放射性核素^(32)P治疗真性红细胞增多症的探讨  

Probe in treatment of polycythemia vera (PV) by the radioactive nuclide ^(32)P

作　　者：李建国[1] 倪济苍[1] 陈显煜[1] 罗加[1] 李小放 

机构地区：[1]重庆医科大学临床学院核医学科,400016

出　　处：《重庆医科大学学报》2000年第3期290-292,297,共4页Journal of Chongqing Medical University

摘　　要：目的 采用放射性核素３２Ｐ治疗真性红细胞增多症（ＰＶ）的疗效、疗程、剂量及生存期等问题的探讨。方法 １３例ＰＶ患者进行３２Ｐ口服或静脉注射治疗，治疗后定期随访，确定有复发者给予下一疗程的治疗。随访时间１～１９年。结果 １３例ＰＶ病人的症状体征均有不同程度的改变，７例缓解（５３．８％），６例好转（４６％），总有效率（１００％）。生存期延长，平均１３．８年。结论 ３２Ｐ治疗ＰＶ疗效好，而且简便、安全，治疗剂量易掌握，无明显的毒副反应，导致转化成其它骨髓增生性疾患（ＭＰＤ）的风险与其自然发展过程无明显差别。一旦ＰＶ的诊断成立，建议及时地采用３２Ｐ治疗。Objective Probe of the curative effect,course of treatment, dosage, existing period etc, in the treatment of polycythmia vera (PV) by the,rdioactive32P. Methods 13 cases with PV were treated by32P taken orally or by intravenous injections. Regular follow-up after treatment was conducted. The ascertained patient having a relapse was given the next course of treatment. Time of follow-up was 1-19 years. Results Symptoms and physical signs of all the 13 patients with PV have changed in varying degrees. Among them 7 cases remitted (53.8%), 6 cases got better (46%). General efficiency is 100% .Existing period prolonged and the averages 13.8 years. Conclusion Treating PV by 32P is more effective than other method, it is simple and convenient and easy to master the dosage in treatment. Risk and its naturally developing process leading to other MPD have no evident difference. Once the diagnosis of PV is tenable, it is better to select 32P first for treatment.

关 键 词：放射性核素 真性红细胞增多症 疗程 剂量 磷32 

分 类 号：R555.105[医药卫生—血液循环系统疾病] R817.53[医药卫生—内科学]